Pre-Conference Meetings Agenda

Sunday, June 8, 2014

• Disparity reduction as a goal of Program Science
• Elimination of leakages in STD/HIV prevention and treatment cascades
• Elimination of delays in STD/HIV prevention and treatment cascades
• Integration of STD/HIV treatment and prevention programs with others such as reproductive health, maternal and child health, and tuberculosis.

Program Science Schedule

Capacity Building Schedule and Introduction

New Federal Guidance on HIV Prevention and Care: Implications for providers of STD and sexual health services
This session will describe new federal guidance on HIV prevention and care that has been disseminated since 2013. These include recommendations on HIV treatment, prevention, testing, and case reporting in the United States.  The presentations will highlight recommendations directed to clinical providers, nonclinical providers, and health department staff who serve persons with HIV or persons at risk for acquiring HIV. They will describe strategies and tools to promote this new guidance, including practical steps for providers of STD and sexual health services and collaborations between health care facilities, health departments, and community-based organizations.

Federal Guidance Introduction and Schedule

STI Vaccines: Toward Global STI Prevention and Control 
This session will explore key findings from NIAID and WHO’s 2013 technical consultation on STI vaccines. The session will begin with an overview of global STI burden and why vaccines are a critical goal for STI prevention and control. Presentations will then examine the current status and exciting prospects for development of the three most promising and urgently needed STI vaccines, against herpes simplex virus, Chlamydia trachomatis, and Neisseria gonorrhoeae. An overview of the process for development and licensure of vaccines from an industry perspective will highlight the “push” and “pull” forces that could guide investment in STI vaccines. The final presentation will provide a synopsis of the global roadmap for progress toward STI vaccine development and introduction.

At the end of the session, there will be an opportunity to discuss as a group how to advance the STI vaccine roadmap and accelerate STI vaccine development for global STI prevention.

STI Vaccines Flyer

Monday, June 9, 2014

Training: STD 101 
This workshop is intended for attendees of the STD Prevention Conference who are interested in STDs but have limited clinical or programmatic experience.  Participants may be community based organization employees, new DIS, program administrators, students, or researchers.   This session will provide participants with a basic understanding of STDs, their clinical issues, national trends, commonality with other diseases, prevention messages, and the STD public health system.

1. Elimination of Mother-to-Child Transmission of congenital syphilis in the Americas
2. Laboratory Update:  Quality Control and Quality Assurance of Syphilis Testing
3. Improving STI Surveillance EffortsFlyer in English and Spanish

Field Services Interest Meeting
The Field Services Branch will offer three pre-conference public trainings in support of the 2014 STD AAPPS funding opportunity announcement. These courses will equip federal, state, and local public health field staff with current information regarding two of the three critical components of the STD AAPPS FOA assessment and assurance.

Courses to be offered:

1. Changes in Surveillance Case Definitions an Update – Revisions to the National Modifiable Diseases Surveillance System (NNDSS) Including the National Electronic Telecommunications System for Surveillance (NETSS)
2. Internet Partner Services Guidelines
3. Health Equity and Social Determinants of Health

These trainings/updates will be delivered through subject matter presentations and interactive Q&A sessions.

Implementing PrEP in STD Clinics Satellite
STD care settings serve large numbers of persons at increased risk of HIV who might benefit from pre-exposure prophylaxis (PrEP) and other prevention services. Among patients in clinical trials who took daily medication as prescribed, PrEP was up to 92% effective in preventing HIV acquisition. A pill containing a fixed-dose combination of tenofovir disoproxil fumarate and emtricitabine was approved by the FDA in 2012 for use as PrEP, yet uptake has been slow among at-risk MSM and heterosexual persons in the United States. In this symposium, we will explore the role of STD health care venues in implementation of PrEP for their patients with indications for its use.

Chairs: Matthew Golden and Karen Hoover

• CDC Recommendations for PrEP Use – Dawn Smith
• Models for PrEP implementation in STD Care Settings
  • Embedded PrEP Clinics in STD Care Settings – Mark Thrun
  • Referral for PrEP in Primary Care Clinics – Julia Dombrowski
• Debate: Which STD Patients Should Be Offered PrEP?
  • All STD Patients – Adaora Adimora
  • All STD Patients Who Are MSM – John Brooks
• Panel Discussion and Q&A – Kyle Bernstein, Matthew Golden, Peter Leone, and Leandro Mena

Please RSVP to STDConf@cdc.gov  and include “Link to Adolescents” in the subject line if you would like to attend this workshop.  The maximum number of participants is 50, so please RSVP soon.

Training: “Office hours” for Targeted Evaluation Planning for STD Program Staff
CDC Division of STD Prevention program evaluation staff will be available during this time to provide individualized, face-to-face technical assistance on evaluation-related questions and tasks for STD program planners and mangers.  STD Program managers are encouraged to use this opportunity to discuss their targeted evaluation plans and obtain feedback on their logic model, narrative, or matrix.  A sign-up sheet will be available in the room throughout the session to allow STD Program Managers to sign up for a particular time slot.

Point of Contact Testing Working Group Description